Scribe Therapeutics Inc. (SCTX) Ownership
SCTX ownership summary
as of October 18, 2026- Institutions
- 56.9% of shares outstanding
- Insiders
- 18.04% of shares outstanding
- Shares outstanding
- 18.9M
- Float
- 6.9M shares available to trade
- Short interest
- — 2.5M shares short
- Days to cover
- 5.68 short interest up 212.1% vs prior month
- Institutions 56.93%
- Insiders 18.04%
- Other investors 25.03%
SCTX top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | ARK Genomic Revolution ETF | 4.17% | 733K | $14.7M | +1,790 (+0.2%) | September 30, 2026 |
| 2 | T. Rowe Price Health Sciences | 3.89% | 684K | $13.7M | +110,300 (+19.2%) | August 31, 2026 |
| 3 | iShares Russell 2000 ETF | 1.44% | 253K | $5.1M | +11,552 (+4.8%) | September 30, 2026 |
| 4 | Franklin Biotechnology Discv A(acc)USD | 1.39% | 244K | $4.9M | — | August 31, 2026 |
| 5 | Franklin Biotechnology Discovery A | 0.77% | 136K | $2.7M | — | August 31, 2026 |
| 6 | iShares Russell 2000 Growth ETF | 0.30% | 53K | $1.1M | −67 (−0.1%) | September 30, 2026 |
| 7 | T. Rowe Price Health Sciences Port | 0.23% | 40K | $809,907 | +7,300 (+22.1%) | August 31, 2026 |
| 8 | ARK Genomic Revolution ETF A USD Acc | 0.23% | 40K | $809,706 | — | September 30, 2026 |
| 9 | iShares Russell 2000 Value ETF | 0.20% | 35K | $710,651 | +54 (+0.2%) | September 30, 2026 |
| 10 | iShares Micro-Cap ETF | 0.17% | 31K | $613,022 | −211 (−0.7%) | September 30, 2026 |
| 11 | Fidelity Nasdaq Composite Index | 0.11% | 19K | $386,480 | +19,247 (0.0%) | August 31, 2026 |
| 12 | JHVIT Health Sciences I | 0.09% | 16K | $311,421 | +6,300 (+68.4%) | August 31, 2026 |
| 13 | Vanguard MStar Total Stk Mkt Idx Invest | 0.09% | 15K | $310,457 | — | August 31, 2026 |
| 14 | EQ/T. Rowe Price Health Sciences IB | 0.06% | 11K | $214,976 | +4,200 (+64.6%) | August 31, 2026 |
| 15 | Global X Russell 2000 ETF | 0.03% | 4,636 | $93,091 | — | September 30, 2026 |
| 16 | State Street Small/Mid Cap Equity Index | 0.02% | 3,200 | $64,256 | +3,200 (0.0%) | September 30, 2026 |
| 17 | Tema Healthcare AI ETF | 0.02% | 3,046 | $61,164 | — | September 30, 2026 |
| 18 | Pacific Select Small-Cap Index I | 0.01% | 2,603 | $52,268 | +2,603 (0.0%) | September 30, 2026 |
| 19 | BlackRock Global Equity Mkt Netrl Instl | 0.01% | 1,084 | $21,767 | +1,084 (0.0%) | July 31, 2026 |
| 20 | GlobalAccess US Sm & Md Cp Eq M Dis GBP | <0.01% | 614 | $12,329 | +34 (+5.9%) | September 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
Who owns SCTX
Institutional investors own 56.9% of Scribe Therapeutics's shares and insiders 18.04%.
Related: SCTX analyst forecast, SCTX key metrics. See the SCTX stock overview for the latest quote and news.
SCTX ownership FAQ
What percentage of Scribe Therapeutics is owned by institutions?
Institutions hold 56.9% of Scribe Therapeutics's shares outstanding; insiders hold 18.04%.
Which funds own Scribe Therapeutics?
The largest fund holders of Scribe Therapeutics are ARK Genomic Revolution ETF (4.17%), T. Rowe Price Health Sciences (3.89%), iShares Russell 2000 ETF (1.44%), Franklin Biotechnology Discv A(acc)USD (1.39%), Franklin Biotechnology Discovery A (0.77%).
How many shares of Scribe Therapeutics are outstanding?
Scribe Therapeutics has 18.9M shares outstanding, of which 6.9M are in the public float.